A prescriber asks why BPC-157 is not on the 503A bulks list, and the answer decides whether you are credible in that room for the rest of the year.
Peptide selling has a specific failure mode: the rep who is fluent in benefits and vague on mechanism, and who does not know which claims are outside the line. That rep is persuasive right up until a physician asks one technical question.
The regulatory picture is the harder half. The FDA compounding advisory committee voted in July 2026, coverage of it was mostly wrong, and reps repeating that coverage are making claims their pharmacy cannot support.
The protocol reference covers all 74 compounds: mechanism of action, indications researched, dosing ranges, routes, contraindications, interactions, and citations. Filterable by category and FDA status, and formatted to print so you can carry a set.
The sales rep compliance guide sets the boundaries per compound under current compounding rules, and the regulatory briefing explains what the July vote actually did. Six of seven peptides were recommended on narrow margins, the committee is advisory, and nothing has been added to any list.
Every compound is sorted by evidence quality: strong preclinical, emerging human data, or limited. The point is knowing which claims you can make without inviting a correction.
Full access to the protocol reference, compliance guides and regulatory briefings.
Get Professional access → Or see everything that is included